Disseminated Nocardia farcinica with multiple cerebral abscesses in a patient receiving induction immunosuppression for autoimmune hepatitis: case report - Summary - MDSpire

Disseminated Nocardia farcinica with multiple cerebral abscesses in a patient receiving induction immunosuppression for autoimmune hepatitis: case report

  • By

  • Akram Alnounou

  • Dimitar Bahariev

  • John Brown

  • Henry Zou

  • Harry Boamah

  • July 16, 2026

Share

Objective:

To report a case of disseminated Nocardia farcinica with multiple cerebral abscesses in a patient receiving immunosuppressive therapy for autoimmune hepatitis.

Approach:
  • Patient Presentation: A 55-year-old man with autoimmune hepatitis and soil exposure presented with cognitive impairment, dysarthria, and right upper extremity weakness.
  • Treatment History: He had received high-dose corticosteroids and azathioprine, with TMP-SMX prophylaxis interrupted 2–4 weeks prior to presentation.
  • Diagnostic Findings: Neuroimaging revealed multiple ring-enhancing intracerebral lesions; Nocardia farcinica was confirmed via aspiration and drainage.
  • Therapeutic Approach: Antimicrobial therapy was adjusted to imipenem-cilastatin and TMP-SMX based on susceptibility testing.
  • Outcome: The patient showed gradual neurological improvement and was discharged to rehabilitation after 18 days.
Key Findings:
  • Disseminated nocardiosis should be considered in immunosuppressed patients with neurological decline and ring-enhancing brain lesions.
  • Microbiological confirmation of Nocardia farcinica was obtained from two sites.
  • Early tissue diagnosis and neurosurgical intervention were critical for the patient's recovery.
Interpretation:

The case highlights the risk of disseminated nocardiosis in patients undergoing immunosuppression and the importance of timely diagnosis and treatment.

Limitations:
  • Limited published reports on CNS nocardiosis associated with autoimmune hepatitis.
  • The case is based on a single patient experience.
Conclusion:

The case reinforces the need for vigilance regarding opportunistic infections in immunosuppressed patients and the effectiveness of susceptibility-guided therapy.

Original Source(s)

Related Content